Mcneil Ab

Johnson & Johnson Consumer Inc.

Kristina Thyresson

Frank J Bunick

Katarina Lindell

Mark Peter Warchol

Elisabeth Sthengel

Jill Nilgard

Folke Morén

Sven-Börje Andersson

Gregory E Koll

Mikael Bisrat

Martin Edman

Carina Siversson

Gerard McNally

Bengt Bosson

Per Steen

Fredrik Nicklasson

Anette SCHLÜTER

Magnus PÅLSSON

ÅSa Waltermo

Darek Dymitrowics

Andreas Hugerth

Sven-Boerje Andersson

Folke Moren

Magnus Palsson

Asa Waltermo

Anette Schluter

Darek Dymitrowicz

Roland Olsson

Joe Luber

The invention relates to a nicotine chewing gum giving an immediate release and uptake of nicotine as well as an extended release and uptake of nicotine as well as describing suitable manufacturing processes for such chewing gum formulations and the use of the chewing gum for the treatment of a human being suffering from cravings from tobacco and/or e-cigarette dependency.

Product and manufacturing process for a gum

The invention relates to a chewing gum comprising at least a gum core comprising nicotine polacrilex, at least a one outer coating covering the core, comprising at least one sugar alcohol or mixtures of sugar alcohols and, at least a one portion fused onto the outer coating, wherein the portion comprises nicotine bitartrate or nicotine ditartrate dihydrate and at least one sugar alcohol or a mixture of sugar alcohols and at least one buffer present in the coating and/or in a portion fused to the coating.

Chewing gum comprising nicotine

The invention relates to a lozenge comprising micronized benzocaine, at least one dissolution enhancer and one or more excipients as well as the use of the lozenge for the treatment of sore throat.

Lozenge comprising micronized benzocaine and polyethylene glycol

Provided are liquid pharmaceutical formulations comprising nicotine in any form for administration essentially to the lungs being acidified and/or alkalized by buffering and/or pH regulation providing for a tof nicotine in arterial blood of a subject within a short period of time after administration. The administration is preferably accomplished by spraying an aerosol into the oral cavity for further distribution essentially into the lungs. Methods for manufacturing the formulation is also disclosed, as are uses of the formulation in therapy, such as therapy for treating addiction to tobacco.

Formulation and use thereof

A liquid pharmaceutical formulation comprising nicotine in any form for administration essentially to the lungs being acidified and/or alkalized by buffering and/or pH regulation providing for a tof nicotine in arterial blood of a subject within a short period of time after administration. The administration is preferably by spraying an aerosol into the oral cavity for further distribution essentially into the lungs. A method for manufacturing said formulation. Use of said formulation in therapy, such as therapy for treating addiction to tobacco.

Growing community of inventors

Lund, Sweden

Kristina Thyresson